Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-medicare

PharmacoEconomics

Volumn 32, Issue 1, 2014, Pages 63-74

  Shaya, Fadia T ^a   Breunig, Ian M ^a   Seal, Brian ^b   Mullins, C Daniel ^a   Chirikov, Viktor V ^a   Hanna, Nader ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Bayer HealthCare Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORBIDITY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DRUG THERAPY; FEMALE; HEALTH CARE COSTS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MEDICARE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84898545565     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0109-7     Document Type: Article

References (21)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-91.
3. Shaw JJ, Shah SA. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev Gastroenterol Hepatol. 2011;5:365-70.
4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-73.
5. Shah SA, Smith JK, Li YF, Ng SC, Carroll JE, Tseng JF. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer. 2011;117:1019-26.
6. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-2.
7. Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol. 2012;83:216-24.
8. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
9. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
10. Thomas MB, O'Beirne JP, Furuse J, Chan ATC, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol. 2008;15:1008-14.
11. Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol. 2010;17:1247-56.
12. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50:89-99.
13. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV3-18.
14. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40:IV104-17.
15. National Cancer Institute. Surveillance epidemiology and end results. 2013. http://seer.cancer.gov. Accessed 28 Feb 2013.
16. Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika. 2000;87:706-10.
17. Lechner M. Identification and estimation of causal effects of multiple treatments under the conditional independence assumption. Econom Eval Labor Mark Policies ZEW Econ Stud. 2001;13:43-58.
18. Lin DY. Linear regression analysis of censored medical costs. Biostatistics. 2000;1:35-47.
19. Griffiths RI, Gleeson ML, Danaes MD, O'Hagan A. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare. Value Health. 2012;15:656-63.
20. White LA, Menzin J, Korn JR, et al. Medical care costs and survival associated with hepatocellular carcinoma among the elderly. Clin Gastroenterol Hepatol. 2012;10:547-54.
21. Nathan H, Schulick RD, Choti MA, et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799-805.